Natera, INC Form 4 insider transactions

Natera, Inc. Director Roy Baynes acquired restricted stock units (RSUs) as compensation for board services and in lieu of retainer fees.

Natera, Inc. reports that SEC and Chief Legal Officer Daniel Rabinowitz sold a significant number of shares under a pre-established trading plan.

Natera, Inc. Director Herm Rosenman sold 16,530 shares of common stock for $250 per share, totaling $4,132,500, as part of a pre-arranged trading plan.

Natera, Inc. Director Rowan E. Chapman sold 2,964 shares of common stock on June 16, 2026, pursuant to a Rule 10b5-1 trading plan.

Natera, Inc. Co-Founder Jonathan Sheena sold 3,150 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Executive Chairman Matthew Rabinowitz sold 100,000 shares of Natera, Inc. common stock under a pre-arranged Rule 10b5-1 trading plan.

Natera, Inc. Director Gail Marcus exercised 11,000 stock options and subsequently sold the shares in a series of transactions.

CEO Steven Chapman liquidated 41,124 shares of Natera common stock through a series of transactions on June 4, 2026.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 3,000 shares of common stock via a Rule 10b5-1 trading plan.

Natera, Inc. director Eric H. Rubin was granted 2,124 restricted stock units as part of his compensation package.

Natera, Inc. Director Roelof Botha reported the sale of common stock totaling over 70,000 shares on June 1, 2026, with transactions executed at weighted average prices ranging from $218.27 to $224.11.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 1,652 shares of common stock to cover tax obligations.

Natera President and Chief Business Officer John Fesko sold 1,438 shares of common stock to cover tax obligations related to RSU vesting.

Natera co-founder Jonathan Sheena executed a series of stock sales totaling 5,006 shares under pre-established 10b5-1 trading plans.

Executive Chairman Matthew Rabinowitz sold 7,708 shares of Natera, Inc. to satisfy tax withholding requirements following the vesting of restricted stock units.

Natera's Chief Financial Officer Michael Brophy sold 795 shares of common stock in early May 2026 for approximately 166,000 dollars.

Natera Co-Founder Jonathan Sheena sold 107 shares of common stock to satisfy tax obligations related to RSU vesting.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 3,405 shares of common stock to cover tax obligations and pursuant to a 10b5-1 trading plan.

John Fesko, President and Chief Business Officer of Natera, Inc., sold 291 shares of common stock to cover tax obligations.

Natera CEO Steven Chapman sold 902 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Natera's Chief Legal Officer Daniel Rabinowitz sold 330 shares of common stock to cover tax withholding requirements.

Natera's Chief Financial Officer Michael Brophy disposed of 5,063 shares through tax-related obligations and a pre-arranged trading plan.

CEO Steven Chapman sold 5,838 shares of Natera common stock to satisfy tax withholding requirements following the vesting of restricted stock units.

Natera's President and Chief Business Officer, John Fesko, sold 1,688 shares to cover tax liabilities following the vesting of restricted stock units.

Solomon Moshkevich, President of Clinical Diagnostics at Natera, sold 2,182 shares to cover tax liabilities resulting from the vesting of restricted stock units.

Chief Legal Officer Daniel Rabinowitz sold 1,861 shares of Natera, Inc. to satisfy tax withholding requirements following RSU vesting.

Natera Director and Co-Founder Jonathan Sheena sold 3,544 shares of common stock in late April 2026, primarily through a pre-arranged trading plan.

Natera, Inc. Director Herm Rosenman acquired 339 shares of common stock through the issuance of Restricted Stock Units.

Natera, Inc. director Gail Marcus acquired 330 shares of common stock through the issuance of restricted stock units as part of her board compensation.

Natera, Inc. director Rowan E. Chapman acquired 336 shares of common stock through the issuance of restricted stock units.